119 related articles for article (PubMed ID: 38501453)
21. Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).
Fournier CN; Bedlack R; Quinn C; Russell J; Beckwith D; Kaminski KH; Tyor W; Hertzberg V; James V; Polak M; Glass JD
JAMA Neurol; 2020 Apr; 77(4):480-488. PubMed ID: 31886839
[TBL] [Abstract][Full Text] [Related]
22. Trajectories of impairment in amyotrophic lateral sclerosis: Insights from the Pooled Resource Open-Access ALS Clinical Trials cohort.
Thakore NJ; Lapin BR; Pioro EP;
Muscle Nerve; 2018 Jun; 57(6):937-945. PubMed ID: 29244213
[TBL] [Abstract][Full Text] [Related]
23. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis.
Rooney J; Burke T; Vajda A; Heverin M; Hardiman O
J Neurol Neurosurg Psychiatry; 2017 May; 88(5):381-385. PubMed ID: 27888187
[TBL] [Abstract][Full Text] [Related]
24. A machine-learning based objective measure for ALS disease severity.
Vieira FG; Venugopalan S; Premasiri AS; McNally M; Jansen A; McCloskey K; Brenner MP; Perrin S
NPJ Digit Med; 2022 Apr; 5(1):45. PubMed ID: 35396385
[TBL] [Abstract][Full Text] [Related]
25. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
Pastula DM; Moore DH; Bedlack RS
Cochrane Database Syst Rev; 2010 Jun; (6):CD005225. PubMed ID: 20556761
[TBL] [Abstract][Full Text] [Related]
26. Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures.
Bakers JNE; de Jongh AD; Bunte TM; Kendall L; Han SS; Epstein N; Lavrov A; Beelen A; Visser-Meily JMA; van den Berg LH; van Eijk RPA
Amyotroph Lateral Scler Frontotemporal Degener; 2022 Nov; 23(7-8):500-507. PubMed ID: 34949141
[No Abstract] [Full Text] [Related]
27. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.
Abdul Wahid SF; Law ZK; Ismail NA; Lai NM
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962
[TBL] [Abstract][Full Text] [Related]
28. Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19.
Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
Muscle Nerve; 2022 Nov; 66(5):593-602. PubMed ID: 36053970
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal evaluation of upper extremity reachable workspace in ALS by Kinect sensor.
de Bie E; Oskarsson B; Joyce NC; Nicorici A; Kurillo G; Han JJ
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Feb; 18(1-2):17-23. PubMed ID: 27813421
[TBL] [Abstract][Full Text] [Related]
30. Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial.
Shefner JM; Jacobsen B; Kupfer S; Malik FI; Meng L; Wei J; Wolff AA; Rudnicki SA
Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):162-169. PubMed ID: 37641579
[TBL] [Abstract][Full Text] [Related]
31. Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19.
Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
Muscle Nerve; 2022 Nov; 66(5):583-592. PubMed ID: 36054038
[TBL] [Abstract][Full Text] [Related]
32. Six-Minute Walk Test as a Measure of Walking Capacity in Ambulatory Individuals With Amyotrophic Lateral Sclerosis.
Sanjak M; Langford V; Holsten S; Rozario N; Patterson CGM; Bravver E; Bockenek WL; Brooks BR
Arch Phys Med Rehabil; 2017 Nov; 98(11):2301-2307. PubMed ID: 28465220
[TBL] [Abstract][Full Text] [Related]
33. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
34. Impact of mode of training and recertification on ALSFRS-R rater performance.
Hamilton J; Mohan P; Kittle G; Shefner JM
Amyotroph Lateral Scler Frontotemporal Degener; 2023 May; 24(3-4):289-294. PubMed ID: 36416415
[TBL] [Abstract][Full Text] [Related]
35. Elimination Rate of Serum Lactate is Correlated with Amyotrophic Lateral Sclerosis Progression.
Zhang YJ; Fan DS
Chin Med J (Engl); 2016 Jan; 129(1):28-32. PubMed ID: 26712429
[TBL] [Abstract][Full Text] [Related]
36. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
Pastula DM; Moore DH; Bedlack RS
Cochrane Database Syst Rev; 2012 Dec; 12():CD005225. PubMed ID: 23235621
[TBL] [Abstract][Full Text] [Related]
37. Plateaus and reversals evaluated by different methods in patients with limb-onset amyotrophic lateral sclerosis.
Hu N; Shen D; Yang X; Cui L; Liu M
J Clin Neurosci; 2022 Mar; 97():93-98. PubMed ID: 35074582
[TBL] [Abstract][Full Text] [Related]
38. Association between nutritional status and disease severity using the amyotrophic lateral sclerosis (ALS) functional rating scale in ALS patients.
Park Y; Park J; Kim Y; Baek H; Kim SH
Nutrition; 2015; 31(11-12):1362-7. PubMed ID: 26429656
[TBL] [Abstract][Full Text] [Related]
39. Validation of the Italian version of self-administered ALSFRS-R scale.
Manera U; Cabras S; Daviddi M; Vasta R; Torrieri MC; Palumbo F; Bombaci A; Grassano M; Solero L; Peotta L; Iazzolino B; Canosa A; Calvo A; Chiò A; Moglia C
Amyotroph Lateral Scler Frontotemporal Degener; 2021 Feb; 22(1-2):151-153. PubMed ID: 32856494
[TBL] [Abstract][Full Text] [Related]
40. How common are ALS plateaus and reversals?
Bedlack RS; Vaughan T; Wicks P; Heywood J; Sinani E; Selsov R; Macklin EA; Schoenfeld D; Cudkowicz M; Sherman A
Neurology; 2016 Mar; 86(9):808-12. PubMed ID: 26658909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
